| Compound | Semax |
|---|---|
| Category | ACTH-derived neuropeptide |
| Class | Neuro, Nootropic, and Cosmetic Peptides |
| Evidence tier | Minimal evidence |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
Semax — a acth-derived neuropeptide — sits in the "Minimal evidence" tier of this catalog. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
A synthetic peptide fragment of ACTH (residues 4-10) registered as a drug in Russia for stroke and optic-nerve conditions. Outside that regional registration, evidence quality is limited.
Mechanism of Action
Semax is reported to influence BDNF expression and central dopaminergic and serotonergic systems after intranasal administration in animal studies.
Research and Evidence
Small Russian trials and a larger observational literature exist; few studies meet Western trial-design standards. It is not approved in the US or EU.
Safety and Side Effects
Registered-product experience in Russia describes a generally tolerable profile; research-grade versions carry the usual unverified-quality caveat.
Frequently Asked Questions
What is the evidence tier of Semax?
Semax is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
Is Semax an approved medicine?
No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Semax?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for Semax studies. [source]
Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.